- Home
- KPLT vs MCRB Comparison
KPLT vs MCRB Comparison
Compare KPLT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPLT | MCRB |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | N/A | 66 |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2M | 41.2M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KPLT | MCRB |
|---|---|---|
| Price | $9.46 | $4.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 129.4K | 48.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.15 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $291,761,000.00 | $789,000.00 |
| Revenue This Year | $18.62 | N/A |
| Revenue Next Year | $15.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.03 | N/A |
| 52 Week Low | $5.30 | $4.01 |
| 52 Week High | $19.68 | $29.98 |
Technical Indicators
Market Signals| Indicator | KPLT | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 68.95 | 35.21 |
| Support Level | $6.05 | N/A |
| Resistance Level | $9.21 | $5.80 |
| Average True Range (ATR) | 0.74 | 0.35 |
| MACD | 0.21 | -0.12 |
| Stochastic Oscillator | 90.21 | 9.40 |
Price Performance
Historical ComparisonAbout KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.